Primecap Management Co. CA Acquires 12,000 Shares of Immunome, Inc. (NASDAQ:IMNM)

Primecap Management Co. CA increased its holdings in Immunome, Inc. (NASDAQ:IMNM) by 4.5% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 280,800 shares of the company’s stock after purchasing an additional 12,000 shares during the period. Primecap Management Co. CA owned approximately 0.47% of Immunome worth $4,105,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Quest Partners LLC bought a new stake in shares of Immunome in the 2nd quarter valued at approximately $81,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Immunome during the second quarter valued at $97,000. Arizona State Retirement System boosted its stake in shares of Immunome by 9.2% in the 2nd quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock valued at $131,000 after purchasing an additional 918 shares in the last quarter. AQR Capital Management LLC boosted its stake in shares of Immunome by 34.6% in the 2nd quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock valued at $194,000 after purchasing an additional 4,129 shares in the last quarter. Finally, Sequoia Financial Advisors LLC bought a new stake in shares of Immunome in the 2nd quarter worth about $206,000. Institutional investors own 44.58% of the company’s stock.

Insiders Place Their Bets

In other Immunome news, CFO Max Rosett sold 14,380 shares of the business’s stock in a transaction dated Thursday, September 19th. The stock was sold at an average price of $16.01, for a total transaction of $230,223.80. Following the completion of the sale, the chief financial officer now directly owns 47,476 shares of the company’s stock, valued at approximately $760,090.76. The trade was a 23.25 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 8.60% of the company’s stock.

Immunome Price Performance

IMNM opened at $9.82 on Friday. The stock has a market capitalization of $612.96 million, a P/E ratio of -1.21 and a beta of 1.82. The company’s 50 day simple moving average is $12.58 and its 200-day simple moving average is $13.61. Immunome, Inc. has a one year low of $6.93 and a one year high of $30.96.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Wedbush restated an “outperform” rating and issued a $33.00 price target on shares of Immunome in a research report on Friday, October 25th. Stephens initiated coverage on Immunome in a report on Friday, November 8th. They issued an “overweight” rating and a $30.00 target price on the stock. Finally, Piper Sandler dropped their price target on Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a report on Thursday, November 14th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, Immunome presently has an average rating of “Buy” and a consensus target price of $28.83.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.